Therefore, inhibition of Bcl-2 inactivation has become a highly attractive strategy in the battle against cancer, and BH3 mimetics are the main category of promising therapeutic agents (Perini et al., 2018; Delbridge and Strasser, 2015). This evidence concerns the gene BCL2 and cancer.